Cirius Therapeutics is a clinical-stage company that develops insulin sensitizer for the treatment of non-alcoholic steatohepatitis. The company developing MSDC-0602K, a next-generation insulin sensitizer for the treatment of nonalcoholic steatohepatitis (NASH). MSDC-0602K is currently being evaluated in a Phase 2b clinical trial. Through its novelinsulin-sensitizing mechanism of action, MSDC-0602K has the potential to resolve the underlying pathophysiology of NASH.Circius Therapeutics focused on the development and commercialization of innovative therapies for the treatment of liver and metabolic diseases. It was founded in 2015 and is based in Kalamazoo, Michigan, United States.

Biotechnology

Pharmaceutical

Therapeutics

Cirius Therapeutics

Bob Baltera

Angeline Shashlo

Jerry Colca

The Leadership Team at Cirius Therapeutics is responsible for steering the company's strategic direction, overseeing clinical and scientific research, and ensuring successful development and commercialization of innovative therapies for liver and metabolic diseases. This team guides the company through its clinical trials, regulatory processes, and market strategies to achieve their objective of bringing advanced treatments like MSDC-0602K for non-alcoholic steatohepatitis (NASH) to patients in need.

Leadership Team

About

Team members

Other teams at Cirius Therapeutics

Scientific Advisory Team